Dr. Reddy’s expands biosimilar offerings in Southeast Asia
Indian firm Dr. Reddy’s Laboratories has entered into a binding agreement with Singapore-based Prestige BioPharma for an exclusive partnership for the supply and commercialisation of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia. Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer. The license agreement grants Dr. Reddy’s the exclusive rights to commercialise the proposed biosimilar in select countries in Latin America and Southeast Asia. Under this partnership, Prestige BioPharma will be responsible for the sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy’s will be responsible for local registrations, marketing and sales in the licensed territories.